Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurophysiological and Acute Pharmacological Studies in FXS Patients
NCT02998151Phase 1Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Jan 2016
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of acamprosate, lovastatin, minocycline and baclofen in Fragile X syndrome (FXS), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoints: Change in EEG Relative Gamma Power at 4 hours and Clinical Global Impressions-Improvement at 4 hours. Started Jan 2016; status: completed.
02
Drugs
acamprosatelovastatinminocyclinebaclofen
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT02998151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998151.